CVS Health (NYSE:CVS) Issues Earnings Results

CVS Health (NYSE:CVS) posted its quarterly earnings data on Wednesday. The pharmacy operator reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.30, Zacks reports. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. CVS Health updated its FY 2025 guidance to 5.750-6.000 EPS.

CVS Health Trading Down 0.0 %

Shares of NYSE:CVS traded down $0.00 during mid-day trading on Friday, hitting $66.37. The stock had a trading volume of 1,601,171 shares, compared to its average volume of 13,128,340. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.59 and a current ratio of 0.80. The company has a market cap of $83.52 billion, a PE ratio of 16.84, a P/E/G ratio of 0.60 and a beta of 0.61. CVS Health has a 12-month low of $43.56 and a 12-month high of $80.75. The company’s 50 day moving average is $50.90 and its 200-day moving average is $56.01.

CVS Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, January 23rd. This represents a $2.66 annualized dividend and a dividend yield of 4.01%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CVS shares. UBS Group cut their target price on shares of CVS Health from $62.00 to $59.00 and set a “neutral” rating on the stock in a research note on Tuesday. TD Cowen increased their price objective on shares of CVS Health from $73.00 to $80.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. Wells Fargo & Company increased their price objective on shares of CVS Health from $68.00 to $73.00 and gave the stock an “overweight” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft upgraded shares of CVS Health from a “hold” rating to a “buy” rating and set a $66.00 target price for the company in a research report on Tuesday, December 3rd. Finally, Leerink Partnrs upgraded shares of CVS Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $70.28.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.